Mechanisms of Atrial Pathoelectrophysiology in HCM
NCT07454135
Summary
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them. The information from this study may help improve future treatments for people who have both HCM and AF.
Eligibility
Inclusion Criteria: * Paroxysmal or persistent atrial fibrillation * Diagnosis of hypertrophic cardiomyopathy * Patient planning to proceed to atrial fibrillation ablation following clinical consultation * Age 18-80 years * Able and willing to provide written informed consent * Able and willing to comply with study follow up requirements Exclusion Criteria: * Any clinical contra-indication to ablation * Any disease limiting life expectancy to \<1 year * Potential participant currently pregnant or breast feeding * Contraindication to MRI including renal dysfunction (eGFR\<30ml/min) * Unable to understand verbal or written explanations given in English
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07454135